(BCRX) BioCryst Pharmaceuticals - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 2.107m USD | Total Return: -18.1% in 12m
Avg Turnover: 34.0M
Qual. Beats: 0
Rev. Trend: 96.7%
Qual. Beats: 0
Warnings
Negative Equity with losses - insolvent profile
Interest Coverage Ratio -5.1 is critical
Beneish M-Score -0.45 > -1.5 - likely earnings manipulation
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
Confidence
BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology firm focused on the development and commercialization of oral and injectable therapies for rare diseases and viral infections. Its primary commercial assets include ORLADEYO, an oral treatment for hereditary angioedema (HAE), and the intravenous antiviral peramivir, marketed globally under brands such as RAPIVAB. The company’s pipeline extends into monoclonal antibodies and protein therapeutics targeting Netherton syndrome, diabetic macular edema, and atopic dermatitis.
The biotechnology sector generally requires high capital expenditure and long lead times for clinical trials, with many firms relying on strategic partnerships to fund late-stage development. BioCryst maintains several such collaborations with governmental agencies like BARDA and international pharmaceutical entities such as Shionogi & Co. to leverage existing infrastructure and distribution networks.
For a deeper look into the companys valuation metrics and financial health, consider exploring the data available on ValueRay.
Headquartered in Durham, North Carolina, BioCryst operates within the rare disease niche, where regulatory pathways like Orphan Drug Designation can provide market exclusivity and specialized pricing power. The company’s current research focus remains on plasma kallikrein inhibitors and OX40 antagonists to address unmet needs in immunology and inflammation.
- ORLADEYO market share expansion drives primary revenue growth and path to profitability
- Navenibart Phase 3 clinical trial results determine long-term competitiveness in HAE market
- Pipeline diversification into Netherton syndrome and atopic dermatitis mitigates single-product risk
- Strategic partnerships and royalty revenue from RAPIVAB stabilize operational cash flow
- Research and development expenses for early-stage protein therapeutics impact near-term margins
| Net Income: -458.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.63 > 0.02 and ΔFCF/TA 68.73 > 1.0 |
| NWC/Revenue: 20.12% < 20% (prev 53.65%; Δ -33.53% < -1%) |
| CFO/TA 0.64 > 3% & CFO 296.3m > Net Income -458.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (242.3m) vs 12m ago 12.54% < -2% |
| Gross Margin: 18.89% > 18% (prev 0.97%; Δ 1.79k% > 0.5%) |
| Asset Turnover: 187.4% > 50% (prev 104.9%; Δ 82.55% > 0%) |
| Interest Coverage Ratio: -5.06 > 6 (EBITDA TTM -374.9m / Interest Expense TTM 75.2m) |
| A: 0.38 (Total Current Assets 373.6m - Total Current Liabilities 195.4m) / Total Assets 465.1m |
| B: -4.79 (Retained Earnings -2.23b / Total Assets 465.1m) |
| C: -0.81 (EBIT TTM -380.6m / Avg Total Assets 472.5m) |
| D: -2.18 (Book Value of Equity -2.23b / Total Liabilities 1.02b) |
| Altman-Z'' = -20.81 = D |
| DSRI: 0.67 (Receivables 109.3m/93.4m, Revenue 885.7m/503.5m) |
| GMI: 5.13 (GM 18.89% / 96.90%) |
| AQI: 1.40 (AQ_t 0.15 / AQ_t-1 0.11) |
| SGI: 1.76 (Revenue 885.7m / 503.5m) |
| TATA: -1.62 (NI -458.0m - CFO 296.3m) / TA 465.1m) |
| Beneish M = -0.45 (Cap -4..+1) = D |
As of May 30, 2026, the stock is trading at USD 8.91 with a total of 3,079,084 shares traded.
Over the past week, the price has changed by +6.45%,
over one month by -0.89%,
over three months by +1.83% and
over the past year by -18.11%.
BioCryst Pharmaceuticals has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy BCRX.
- StrongBuy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.3 | 139.1% |
P/E Forward = 71.9424
P/S = 2.3789
P/B = 56.5858
P/EG = 9.3878
Revenue TTM = 885.7m USD
EBIT TTM = -380.6m USD
EBITDA TTM = -374.9m USD
Long Term Debt = 802.4m USD (from longTermDebt, last quarter)
Short Term Debt = 43.4m USD (from shortTermDebt, last quarter)
Debt = 873.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 15.4m
Net Debt = 634.2m USD (calculated: Debt 873.5m - CCE 239.3m)
Enterprise Value = 2.74b USD (2.11b + Debt 873.5m - CCE 239.3m)
Interest Coverage Ratio = -5.06 (Ebit TTM -380.6m / Interest Expense TTM 75.2m)
EV/FCF = 9.34x (Enterprise Value 2.74b / FCF TTM 293.6m)
FCF Yield = 10.71% (FCF TTM 293.6m / Enterprise Value 2.74b)
FCF Margin = 33.15% (FCF TTM 293.6m / Revenue TTM 885.7m)
Net Margin = -51.71% (Net Income TTM -458.0m / Revenue TTM 885.7m)
Gross Margin = 18.89% ((Revenue TTM 885.7m - Cost of Revenue TTM 718.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 5.89 (Enterprise Value 2.74b / Total Assets 465.1m)
Interest Expense / Debt = 8.60% (Interest Expense 75.2m / Debt 873.5m)
Taxrate = 1.32% (3.53m / 267.4m)
NOPAT = -375.6m (EBIT -380.6m * (1 - 1.32%)) [loss with tax shield]
Current Ratio = 1.91 (Total Current Assets 373.6m / Total Current Liabilities 195.4m)
Debt / Equity = -1.58 (negative equity) (Debt 873.5m / totalStockholderEquity, last quarter -553.8m)
Debt / EBITDA = -1.69 (negative EBITDA) (Net Debt 634.2m / EBITDA -374.9m)
Debt / FCF = 2.16 (Net Debt 634.2m / FCF TTM 293.6m)
Total Stockholder Equity = -370.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -96.92% (Net Income -458.0m / Total Assets 465.1m)
RoE = -24.66% (Net Income TTM -458.0m / Total Stockholder Equity 1.86b)
RoCE = -14.31% (EBIT -380.6m / Capital Employed (Equity 1.86b + L.T.Debt 802.4m))
RoIC = -144.4% (out of range, set to none) (NOPAT -375.6m / Invested Capital 260.2m)
WACC = 8.00% (E(2.11b)/V(2.98b) * Re(7.79%) + D(873.5m)/V(2.98b) * Rd(8.60%) * (1-Tc(0.01)))
Discount Rate = 7.79% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 8.55%
[DCF] Terminal Value 75.44% ; FCFF base≈293.6m ; Y1≈294.8m ; Y5≈312.3m
[DCF] Fair Price = 16.61 (EV 4.86b - Net Debt 634.2m = Equity 4.22b / Shares 254.2m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.08 | # QB: 0
Revenue Correlation: 96.67 | Revenue CAGR: 48.16% | SUE: 0.06 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.24 | Chg30d=+83.80% | Revisions=N/A | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.10 | Chg30d=-21.23% | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=0.56 | Chg30d=+18.20% | Revisions=+33% | GrowthEPS=-11.0% | GrowthRev=-23.4%
EPS next Year (2027-12-31): EPS=0.68 | Chg30d=-15.21% | Revisions=-14% | GrowthEPS=+20.3% | GrowthRev=+8.5%
[Analyst] Revisions Ratio: +33%